T cells armed with anti-CD3 × anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. - Gall,J.M.; Davol,P.A.; Grabert,R.C.; Deaver,M.; Lum,L.G. (Exp Hematol, 2005)